Investing in New Frontiers
Orum is a global biopharmaceutical company bringing life-changing therapies to patients by combining the power of the emerging field of protein degraders with the precision of antibodies.
Our company exists to cure cancer patients and beyond, through innovative research and development of therapeutics and technologies.
We aim to succeed by maintaining our leadership in Degrader Antibody Conjugate (DAC) technology, fostering an engaged culture, and cultivating high talent density.
Our collaborative, self-driven approach, coupled with our commitment to openness and truth, drives our mission to transform patients' lives.
|| Stock chart
|| Upcoming Event
|| Events & Presentations
|| Press Releases
|| Investor Toolkit
10th AGM 2026 Amendment Report Notice of Shareholders Meeting
VIEW PDF >
9th AGM 2025 Amendment Report Notice of Shareholders Meeting
VIEW PDF >
Results of the 10th Annual General Meeting
VIEW PDF >
SEC Filings /
Dart
VIEW PDF >
EVENTS & PRESENTATIONS
MAR 16, 2026
Webcast Registration
Notice of the 10th Annual General Meeting 2026
DEC 09, 2025
Conference
J.P Morgan Healthcare Conference
JAN 16, 2026
Conference
ASH Annual Meeting
NOV 25, 2025
Conference
Corporate Day Hosted by Mirae Asset
First Quarter 2026
Financial Results
DOWNLOAD ↓
Investors &
Scientific Presentations
DOWNLOAD ↓
Annual Report
DOWNLOAD ↓
10th AGM 2026 Amendment Report Notice of Shareholders Meeting
9th AGM 2025 Amendment Report Notice of Shareholders Meeting
Investor Toolkit
Results of the 10th Annual General Meeting
VIEW ALL RESOURCES AND DOCUMENTS >
SEC Filings /
Dart